Clinical Trials Sponsored by NKMax America, Inc.

Total 1204 results

Bausch Health Americas, Inc.

Completed

Compassionate Use Study of Methylnaltrexone

Opioid-induced Constipation

United States
Bausch Health Americas, Inc.

Completed

Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy

Hepatic Encephalopathy

United States, Canada
Bausch Health Americas, Inc.

Terminated

Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

Psoriasis

United States, Australia, France, Canada, Denmark
Bausch Health Americas, Inc.

Completed

Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C) (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United States
Bausch Health Americas, Inc.

Completed

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United States
Bausch Health Americas, Inc.

Completed

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) (CIBS)

Irritable Bowel Syndrome Characterized by Constipation

United States
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
American Cancer Society, Inc.

Completed

Metabolomics and Breast Cancer Risk in a Nested Case-control Study of the Cancer Prevention Study-II Nutrition Cohort

Breast Cancer
Bausch Health Americas, Inc.

Completed

Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects

Psoriasis

United States, Australia, New Zealand
Bausch Health Americas, Inc.

No longer available

Compassionate Use Study of Pergolide in Patients With Parkinson's Disease

Parkinson Disease
Bausch Health Americas, Inc.

Completed

Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B

Hepatitis B, Chronic
Bausch Health Americas, Inc.

Completed

A Study Comparing the Effectiveness and Safety of Extended Release Tramadol HCl at 100 mg, 200 mg and 300 mg Doses to Placebo for the Treatment of Moderate to Severe Pain Due to Osteoarthritis (OA)

Chronic Pain
Bausch Health Americas, Inc.

Completed

A Study Comparing the Effectiveness and Safety of Extended Release Tramadol Versus Placebo for the Treatment of Osteoarthritis (OA) of the Knee

Chronic Pain
Bausch Health Americas, Inc.

Completed

A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products

Acne Vulgaris

United States
Bausch Health Americas, Inc.

Completed

Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face

Acne Vulgaris

United States
Bausch Health Americas, Inc.

Recruiting

Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity (CARE)

Psoriasis

Canada
Bausch Health Americas, Inc.

Recruiting

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

United States
Bausch Health Americas, Inc.

Recruiting

A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis

Psoriasis

United States, Panama
Bausch Health Americas, Inc.

Enrolling by invitation

LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis

Psoriasis

United States
American Cancer Society, Inc.

Completed

Health and Energy Through Active Living Every Day After Cancer Intervention for Cancer Survivors (HEALED)

Depression | Quality of Life | Fatigue | Sleep | Anxiety | Cognitive Decline

United States
Bausch Health Americas, Inc.

Completed

Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel

Acne Vulgaris

United States, Belgium, Canada
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)

Atopic Dermatitis

United States
Bausch Health Americas, Inc.

Completed

Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function

Healthy Males

United States
Bausch Health Americas, Inc.

Completed

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Inhaled Virazole Administered Via Air-Jet Nebulizer in Healthy Volunteers

Healthy

Canada
Bausch Health Americas, Inc.

Completed

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC) (OIC)

Constipation

United States
Bausch Health Americas, Inc.

Completed

Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea (ADVENT)

HIV Associated Diarrhea

United States, Puerto Rico
Bausch Health Americas, Inc.

Completed

(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.

Ulcerative Colitis

United States, Canada
Bausch Health Americas, Inc.

Terminated

AMG 827 in Subjects With Psoriatic Arthritis

Psoriatic Arthritis

United States, Canada
Bausch Health Americas, Inc.

Terminated

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis (AMAGINE-2)

Moderate to Severe Plaque Psoriasis

United States, Austria, France, Poland, Australia, Czechia, Canada, Hungary, Portugal, Spain, Netherlands
Bausch Health Americas, Inc.

Terminated

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3)

Plaque Psoriasis

United States, Belgium, Italy, Hungary, Poland, Australia, France, Greece, Russian Federation, Latvia, Canada
Bausch Health Americas, Inc.

Completed

12-Week Study of Plecanatide for CIC (The CIC3 Study)

Chronic Idiopathic Constipation

United States, Canada
Bausch Health Americas, Inc.

Completed

(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

Ulcerative Colitis

United States, Canada, India, Mexico
Bausch Health Americas, Inc.

Completed

Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers

Pharmacokinetic
Bausch Health Americas, Inc.

Terminated

Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201

Hepatitis B, Chronic
Bausch Health Americas, Inc.

Completed

Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects

Healthy Adult Subjects

United States
Bausch Health Americas, Inc.

Completed

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS) (TARGET 1)

Non-Constipation Irritable Bowel Syndrome

United States, Canada
Bausch Health Americas, Inc.

Completed

Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan

Healthy Adults

United States
Bausch Health Americas, Inc.

Completed

Open-Label Treatment Extension of Protocol MNTX 301

Terminal Illness

United States
Bausch Health Americas, Inc.

Completed

Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris

Tinea Pedis | Tinea Cruris

Dominican Republic, Honduras
Bausch Health Americas, Inc.

Completed

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function

Renal Impairment

United States
Bausch Health Americas, Inc.

Completed

Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Ileus

Postoperative Ileus

United States
Bausch Health Americas, Inc.

Completed

Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX

Healthy Adult Subjects

United States
Bausch Health Americas, Inc.

Completed

Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose

Healthy Subjects

United States
Bausch Health Americas, Inc.

Completed

Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.

Diarrhea

United States
Bausch Health Americas, Inc.

Completed

Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus

Post Operative Bowel Dysfunction

Germany, Italy, United States, Hungary, Korea, Republic of, South Africa, Poland, Australia, Romania, Former Serbia and Montenegro
Bausch Health Americas, Inc.

Completed

Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI) (SoFI)

Fecal Incontinence

United States
Bausch Health Americas, Inc.

Completed

Diarrhea Predominant Irritable Bowel Syndrome in Females

Irritable Bowel Syndrome

United States

3

Subscribe